comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-01 00:59:15 - browse：6968

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Copay coupons to count toward deductibles, after Biden court move

WSS

Biotech venture capitalists face new demands from investors

Test for long Covid? Researchers find new clue in blood samples

FDA clears AI tool for detecting skin cancer

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Allen Institute goes after foundational questions, CEO Costa says

leisure time

comprehensive

hotspot

At least 13 dead in Texas as scorching temps continue

Medicare Advantage overpayments discussion gets experts fired up

Affirmative action in medical school literally saved lives

Physician assistants need a new name. Here's what it should be

As demand for Covid shots wanes, Moderna seeks its next success

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

How to save PrEP access — and even expand it

Francis Collins on trust in science and how Covid communications failed

Sports medicine is finally prioritizing gender equality

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

entertainment

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Prior authorization will have to move faster under new Biden rule

EU regulator recommends expanding Mounjaro approval to obesity

My yearlong odyssey to get my son’s ADHD medication covered

Profiling embryos to choose those with higher IQs is almost a reality

eGenesis tests gene

focus

focus

focus

explore